Sign In
Buy GILD
$125.05
+0.180 (+0.144%)
At Close: Jun 23, 2026
Gilead Foundation Commits Over $3 Million to Address Food Insecurity
08:30am, Monday, 24'th Nov 2025
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Foundation today announced that it has committed over $3 million in grants to expand access to food in communities across the United States. Gilead Foundat
Bank Julius Baer & Co. Ltd Zurich Reduces Stock Position in Gilead Sciences, Inc. $GILD
04:38am, Sunday, 23'rd Nov 2025
Bank Julius Baer and Co. Ltd Zurich trimmed its position in Gilead Sciences, Inc. (NASDAQ: GILD) by 14.9% in the undefined quarter, according to the company in its most recent disclosure with the Secu
American Century Companies Inc. Boosts Stock Holdings in Gilead Sciences, Inc. $GILD
03:52am, Sunday, 23'rd Nov 2025
American Century Companies Inc. grew its holdings in shares of Gilead Sciences, Inc. (NASDAQ: GILD) by 47.5% during the undefined quarter, according to its most recent 13F filing with the Securities a
Gilead Sciences: Rating Upgrade Warranted On HIV Division Strength
04:46pm, Thursday, 20'th Nov 2025
Gilead Sciences, Inc. continues to outperform, driven by its dominant HIV division and strong Q3 results that surpassed analyst expectations. GILD's HIV portfolio, led by Biktarvy and new launch Yeztu
Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock
10:06am, Thursday, 20'th Nov 2025
Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Aspen Neuroscience Announces $115 Million Series C Financing to Accelerate Personalized Cell Therapy Programs
07:02am, Thursday, 20'th Nov 2025
SAN DIEGO , Nov. 20, 2025 /PRNewswire/ -- Aspen Neuroscience, Inc., a clinical-stage biotechnology company pioneering autologous regenerative therapies, today announced the closing of a $115 million
Gilead Sciences, Inc. (GILD) Presents at Jefferies London Healthcare Conference 2025 Transcript
11:23am, Wednesday, 19'th Nov 2025
Gilead Sciences, Inc. ( GILD ) Jefferies London Healthcare Conference 2025 November 19, 2025 9:00 AM EST Company Participants Andrew Dickinson - Chief Financial Officer Conference Call Participants Am
Alteri Wealth LLC Grows Position in Gilead Sciences, Inc. $GILD
03:08am, Wednesday, 19'th Nov 2025
Alteri Wealth LLC lifted its position in Gilead Sciences, Inc. (NASDAQ: GILD) by 11.5% during the undefined quarter, according to its most recent disclosure with the SEC. The fund owned 5,181 shares o
FOSTER CITY, Calif. & MBABANE, Eswatini--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the delivery of first shipments of lenacapavir – Gilead's twice-yearly injectable HIV-1
Advisors Capital Management LLC Cuts Holdings in Gilead Sciences, Inc. $GILD
06:00am, Saturday, 15'th Nov 2025
Advisors Capital Management LLC lowered its stake in shares of Gilead Sciences, Inc. (NASDAQ: GILD) by 15.9% in the second quarter, according to the company in its most recent Form 13F filing with the
GILD's Investigational Regimen for HIV Treatment Meets Primary Goal
09:16am, Friday, 14'th Nov 2025
Gilead's ARTISTRY-1 success boosts shares as its once-daily bictegravir/lenacapavir combo proves non-inferior to complex regimens.
1,140 Shares in Gilead Sciences, Inc. $GILD Acquired by Avalon Trust Co
04:12am, Friday, 14'th Nov 2025
Avalon Trust Co purchased a new stake in Gilead Sciences, Inc. (NASDAQ: GILD) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commiss
ABN Amro Investment Solutions Takes $5.30 Million Position in Gilead Sciences, Inc. $GILD
03:15am, Friday, 14'th Nov 2025
ABN Amro Investment Solutions bought a new position in shares of Gilead Sciences, Inc. (NASDAQ: GILD) during the second quarter, according to its most recent disclosure with the Securities and Exchang
Gilead's One-Pill HIV Treatment Shows Promise In Late-Stage Trial
01:55pm, Thursday, 13'th Nov 2025
Gilead Sciences Inc. (NASDAQ: GILD) on Thursday shared topline results from the Phase 3 ARTISTRY-1 trial.
Can Gilead Stock Outrun Regeneron In The Next Rally?
09:00am, Thursday, 13'th Nov 2025
Regeneron Pharmaceuticals stock increased by 19% over the past month driven by strong third-quarter earnings and robust sales of its flagship drugs, Dupixent (for eczema and other inflammatory conditi
